SCHEMBL20652982

SCHEMBL20652982

Cc1ccc(-c2nc3c([nH]2)c(=O)[nH]c(=O)n3C(C)C)c(Cl)n1

nearest known ligand 0.44

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 3/20 0.36
▸ ALDH1A1 P00352 2/20 0.36
▸ KDM4E B2RXH2 1/20 0.36
▸ GLA P06280 1/20 0.36
▸ CASP1 P29466 1/20 0.36
▸ CASP7 P55210 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ HSD17B10 Q99714 1/20 0.36
▸ METAP2 P50579 2/20 0.36
▸ ADORA2A P29274 3/20 0.36
▸ ADORA2B P29275 3/20 0.36
▸ ADORA1 P30542 1/20 0.34
▸ MEN1 O00255 2/20 0.33
▸ TSHR P16473 1/20 0.33
▸ CYP1A2 P05177 1/20 0.33
▸ MTOR P42345 1/20 0.33
▸ FGFR1 P11362 1/20 0.32
▸ FGFR2 P21802 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL22105441 0.83 ALDH1A1 (0.36) KMT2AALDH1A1KDM4EGLACASP1
SCHEMBL20652968 0.82 ADORA1 (0.53) KMT2AALDH1A1KDM4EGLACASP1
SCHEMBL20652780 0.77 KMT2A (0.37) KMT2AALDH1A1KDM4EGLACASP1
SCHEMBL20652782 0.76 ADORA2A (0.34) KMT2AALDH1A1KDM4EGLACASP1
SCHEMBL22109857 0.73 MTOR (0.34) KMT2AALDH1A1KDM4EGLACASP1
SCHEMBL20652980 0.73 KDM4E (0.53) KMT2AALDH1A1KDM4ESMN1; SMN2HSD17B10
SCHEMBL20656214 0.71 KDM4E (0.53) KMT2AALDH1A1KDM4EGLACASP1
SCHEMBL20655914 0.70 KDM4E (0.47) KMT2AALDH1A1KDM4EGLACASP1
SCHEMBL2333182 0.66 ADORA2B (0.61) ADORA2AADORA2BADORA1
SCHEMBL22560007 0.65 PNP (0.43) KMT2AALDH1A1KDM4EHSD17B10MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3652176-B1 SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INT (DE) 2021-12-15 — — EP disclosed
US-10329292-B2 Substituted xanthine derivatives BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-06-25 — — US disclosed
WO-2019011802-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — WO disclosed
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2019-01-17 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10329292-B2 Substituted xanthine derivatives TRPC5, TRPV1, TRPC4 KMT2A 4180/4885ALDH1A1 1347/4885KDM4E 3884/4885
US-20190016722-A1 NOVEL SUBSTITUTED XANTHINE DERIVATIVES TRPC5, TRPC4, TRPV1 KMT2A 4155/4885ALDH1A1 1488/4885KDM4E 3789/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback